Drug intelligence / Profile preview

IGC-503

Development stage: Preclinical
Lead developer: IGC Pharma
Modality: Small Molecules

Overview

IGC-503 is a small molecule drug candidate being developed by IGC Pharma for the treatment of Alzheimer's disease. It is designed to target and reduce the accumulation of amyloid-beta (Aβ) plaques in the brain, which are a hallmark of Alzheimer's pathology. By inhibiting the aggregation of Aβ or promoting its clearance, IGC-503 aims to slow the progression of cognitive decline. The drug is currently in the preclinical development stage, with the developer focusing on its potential to modify the disease course rather than just treating symptoms. It represents part of IGC's broader pipeline of CNS-focused therapies, which includes both cannabinoid and non-cannabinoid molecules.

Targets

Cu (Copper ion)Aβ oligomers (Amyloid-β oligomers)

Beyond the preview

Go deeper on IGC-503.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IGC-503.

Explore the full profile